In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

AZ and Daiichi Sankyo already claimed FDA approval for the HER2-low indication in the US last summer, adding to Enhertu's lengthening list of indications, which also includes second- and third ...

Specifically, Enhertu treats the following cancers in certain situations. Depending on the type of cancer, it must be HER2-positive or HER2-low (have a high level of a protein called HER2 ...

Rachel Davies is not able to access the life-extending drug because she lives in Wales.

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Enhertu is a combination of a chemotherapy ... In brief, the cancers are: HER2-positive breast cancer unresectable or metastatic HER2-low breast cancer unresectable or metastatic non-small cell ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

Enhertu demonstrates promising results in HER2-low patients post-Trodelvy, achieving a 34.8% ORR and 7.0 months PFS. Real-world studies are crucial for assessing clinical benefits beyond controlled ...

In 2022, the FDA approved Enhertu for “HER2-low” breast cancer patients who had prior chemotherapy based on the Destiny-BREAST04 trial, which demonstrated a 40%-50% reduction in risk of ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has accepted the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu for HER2-low ...

ENHERTU (5.4 mg/kg) is approved in more than 65 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have ...